In this study, 96 patients who were inadequately controlled with a sulfonylurea drug alone were randomly assigned to receive bedtime intermediate-acting insulin (BI) plus either glyburide, metformin, glyburide plus metformin, or a second injection of intermediate-acting insulin in the morning. After 12 months, the group receiving bedtime insulin plus metformin alone had significantly less weight gain (panel A) and lower A1C values (panel B) than the other three treatment groups.
Redrawn from Yki-Järvinen H, Ryysy L, Nikkilä K, et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1999; 130:389.
